Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:Suboxone_film
|
| gptkbp:acquisition |
Buprenorphine products
|
| gptkbp:ceo |
gptkb:Shlomo_Ben-Haim
|
| gptkbp:employees |
approximately 500
|
| gptkbp:focus |
substance use disorder
|
| gptkbp:founded |
gptkb:2014
|
| gptkbp:headquarters |
gptkb:Richmond,_Virginia,_USA
|
| https://www.w3.org/2000/01/rdf-schema#label |
Indivior
|
| gptkbp:known_for |
gptkb:Suboxone
|
| gptkbp:market |
global
|
| gptkbp:parent_company |
gptkb:Reckitt_Benckiser
|
| gptkbp:partnerships |
various healthcare organizations
|
| gptkbp:research_focus |
opioid addiction treatments
|
| gptkbp:revenue |
$800 million (2020)
|
| gptkbp:subsidiary |
Indivior PLC
|
| gptkbp:traded_on |
gptkb:London_Stock_Exchange
|
| gptkbp:website |
www.indivior.com
|